NeoStem (AMEX:NBS): BusinessWeek Mention Print E-mail
Friday, 19 June 2009 16:34
NeoStem, Inc. (AMEX:NBS) is a pioneer and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications. The Company's business model includes generating revenue through ongoing fees associated with a minimally invasive, proprietary stem cell collection process, in addition to fees charged to the centers for marketing and long-term storage.

The Company was recently profiled at BusinessWeek online and will appear in the June 29 print magazine edition.

Pro-Active Research Group initiated coverage of NeoStem on 5/27/09 with a speculative buy rating and $5/share long-term price target. The PDF report is available to view or download for free at the BioMedReports.com stock research reports section.

The following are links to eight YouTube videos listed as favorites on my channel related to NeoStem and promising uses of adult stem cells, including (1) an interview with NeoStem's CEO, Robin Smith; (2) peripheral vascular disease; (3) multiple sclerosis (MS); (4) orthopedic surgery; (5) diabetes; (6) heart attack; (7) heart valve development; and (8) lupus.

Disclosure: No positions.




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and

Error. Page cannot be displayed. Please contact your service provider for more details. (30)

investor relation services from various entities and
firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
blog comments powered by Disqus
 
BMR:1